Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Links shared publicly online about this topic.

347
total visits

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

View full resource at news-medical.net

Tags: Seizure, Epilepsy, Anxiety Disorder, Posttraumatic Stress Disorder, Disease and Condition, Phase 2 Clinical Trial, Stress Management, News